Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad mulls split of pharma and Dx units

This article was originally published in Clinica

Executive Summary

Myriad Genetics could have spun off its pharma business by the end of the year, keeping hold of its more lucrative molecular diagnostics operations. This is one of "several strategic alternatives" that the Salt Lake City, Utah firm said its board of directors was currently considering in order to maximise shareholder value. The company said it intends to announce a decision by the end of the year. Myriad's molecular diagnostics business – which sells genetic tests for various hereditary cancers, including breast, ovarian and colorectal – is the company's main money-spinner, with revenues increasing steadily over the last several quarters. The pharmaceutical business contributes to only a fraction of Myriad's revenue, which is generated mainly from research and licensing fees.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel